SCP
VNDA icon

Seizert Capital Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Seizert Capital Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-48,244
Closed -$357K – 198
2022
Q4 		$357K Buy
+48,244
New +$470K 0.02% 177

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Seizert Capital Partners's VNDA Position: Q1 2023 in Review

Seizert Capital Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 48,244 shares — an estimated $357K sold.

Seizert Capital Partners first reported a position in VNDA in Q4 2022 and held it in 1 quarter. The position peaked at $357K in Q4 2022. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

  • Seizert Capital Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Seizert Capital Partners sold 48,244 Vanda Pharmaceuticals shares in Q1 2023, an estimated $357K.
  • Seizert Capital Partners first reported a position in Vanda Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Seizert Capital Partners's Vanda Pharmaceuticals position peaked at $357K in Q4 2022.
  • 177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Seizert Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.